Alto Neuroscience Inc. (NYSE: ANRO) announced that its Phase 2 proof-of-concept trial of ALTO-101 for cognitive impairment associated with schizophrenia ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE